These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 31130397)
1. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor. Gondran H; Thebaud E; Moreau A; Le Rhun M; Touchefeu Y; Regenet N; Musquer N Pancreatology; 2019 Jun; 19(4):566-568. PubMed ID: 31130397 [TBL] [Abstract][Full Text] [Related]
2. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report. Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531 [TBL] [Abstract][Full Text] [Related]
3. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174 [TBL] [Abstract][Full Text] [Related]
4. Primary pancreatic perivascular epithelioid cell tumor (PEComa): A surgical enigma. A systematic review of the literature. Zizzo M; Ugoletti L; Tumiati D; Castro Ruiz C; Bonacini S; Panebianco M; Sereni G; Manenti A; Lococo F; Carlinfante G; Pedrazzoli C Pancreatology; 2018 Apr; 18(3):238-245. PubMed ID: 29478828 [TBL] [Abstract][Full Text] [Related]
5. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa. Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639 [TBL] [Abstract][Full Text] [Related]
6. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature. Starbuck KD; Drake RD; Budd GT; Rose PG Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946 [TBL] [Abstract][Full Text] [Related]
7. Pancreatic perivascular epithelioid cell tumor: A case report with clinicopathological features and a literature review. Jiang H; Ta N; Huang XY; Zhang MH; Xu JJ; Zheng KL; Jin G; Zheng JM World J Gastroenterol; 2016 Apr; 22(13):3693-700. PubMed ID: 27053862 [TBL] [Abstract][Full Text] [Related]
8. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055 [TBL] [Abstract][Full Text] [Related]
9. TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review. Purwar R; Soni K; Shukla M; Verma A; Kumar T; Pandey M World J Surg Oncol; 2022 Mar; 20(1):62. PubMed ID: 35232443 [TBL] [Abstract][Full Text] [Related]
11. Perivascular epithelial cell tumor (PEComa) of the pancreas: A case report and review of literature. Zhang S; Chen F; Huang X; Jiang Q; Zhao Y; Chen Y; Zhang J; Ma J; Yuan W; Xu Q; Zhao J; Wang C Medicine (Baltimore); 2017 Jun; 96(22):e7050. PubMed ID: 28562565 [TBL] [Abstract][Full Text] [Related]
12. A case of pancreatic PEComa with prominent inflammatory cell infiltration: the inflammatory subtype is a distinct histologic group of PEComa. Tsukita H; Koyama K; Ishinari T; Takahashi A; Miyabe K; Umakoshi M; Yoshida M; Kudo-Asabe Y; Nishida A; Otsuka N; Yasui O; Kato I; Fukushima N; Goto A Diagn Pathol; 2024 Apr; 19(1):59. PubMed ID: 38622713 [TBL] [Abstract][Full Text] [Related]
13. Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report. Weeber F; Koudijs MJ; Hoogstraat M; Besselink NJ; VAN Lieshout S; Nijman IJ; Cuppen E; Offerhaus GJ; Voest EE Anticancer Res; 2015 Jun; 35(6):3399-403. PubMed ID: 26026101 [TBL] [Abstract][Full Text] [Related]
14. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Italiano A; Delcambre C; Hostein I; Cazeau AL; Marty M; Avril A; Coindre JM; Bui B Ann Oncol; 2010 May; 21(5):1135-7. PubMed ID: 20215136 [No Abstract] [Full Text] [Related]
15. Perivascular Epithelioid Cell Tumor (PEComa) of Pancreas Diagnosed Preoperatively by Endoscopic Ultrasound-Guided Fine-Needle Aspiration: A Case Report and Review of Literature. Collins K; Buckley T; Anderson K; Karasik M; Ligato S Diagn Cytopathol; 2017 Jan; 45(1):59-65. PubMed ID: 27628738 [TBL] [Abstract][Full Text] [Related]
16. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). Bergamo F; Maruzzo M; Basso U; Montesco MC; Zagonel V; Gringeri E; Cillo U World J Surg Oncol; 2014 Feb; 12():46. PubMed ID: 24575738 [TBL] [Abstract][Full Text] [Related]
18. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. Gennatas C; Michalaki V; Kairi PV; Kondi-Paphiti A; Voros D World J Surg Oncol; 2012 Sep; 10():181. PubMed ID: 22943457 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports. Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891 [TBL] [Abstract][Full Text] [Related]